The Filing Desk

iBio vs Serina Therapeutics

iBio IBIO · Serina Therapeutics SER · Pharmaceuticals

iBio reported revenue of $0 million in fiscal 2026, about the same as Serina Therapeutics' $0 million in fiscal 2025. iBio's revenue fell 75.0% in its latest year, and Serina Therapeutics' grew 132.1%. iBio had an operating margin of -35141.0%, against -18478.5% at Serina Therapeutics. Free cash flow was −$24 million at iBio and −$18 million at Serina Therapeutics. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.

Side by side

iBioSerina Therapeutics
Latest fiscal yearFY2026, Jun 30, 2026FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth−75.0%132.1%
Revenue growth a year, last 5 years−47.0%−24.2%
Gross margin——
Operating margin−35,141.0%−18,478.5%
Net margin−33,044.0%−14,755.4%
Free cash flow−$24M−$18M
Free cash flow margin−23,796.0%−13,856.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count891.1%38.5%
Last close$0.80$1.20
P/E at the last close——
Insider trades, last 12 monthsbought $98,110, sold $0bought $77,955, sold $335,128
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
iBioSerina Therapeutics
Operating margin
Percent of revenue
iBioSerina Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
iBioSerina Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the iBio and Serina Therapeutics pages.